Men's health
Your PSA Came Back High: What the Number Means and What Happens Next
A PSA result above the expected range is a signal to follow up, not a diagnosis — PSA rises with many benign prostate conditions, not only cancer. The next step is a conversation with a primary-care clinician or urologist about repeating the test and what further evaluation makes sense. It is not an emergency.
Talk to a clinician
Nina Osei, NP — Nurse Practitioner
checkups, refills & skin. Gale can match you with a licensed clinician for a visit.
Find care →Why is PSA a prostate marker and not a prostate cancer test?
PSA is produced by prostate tissue. Elevated PSA is non-specific: it rises with benign prostate conditions, inflammation, and certain activities — not only cancer 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. A high result means your prostate is producing more PSA than expected for your age and size, but it does not mean cancer is present.
Most guidelines do not use a single universal cutoff for "normal" PSA because interpretation depends on your age, prostate size, the trend over time, and your individual risk factors 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups. Importantly, many men with prostate cancer have a PSA in the "normal" range, and many men with elevated PSA do not have cancer. PSA is a screening signal — a reason to look further — not a definitive answer.
What commonly raises PSA besides cancer?
The most frequent causes of an elevated PSA, in rough order of how commonly they arise:
Benign prostatic hyperplasia (BPH) — the most common reason for a moderately elevated PSA in men over 50. The prostate growing with age naturally produces more PSA 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups.
Prostatitis — inflammation or infection of the prostate can spike PSA considerably, sometimes in men who feel entirely well. Bacterial prostatitis and non-bacterial inflammation both raise it.
Recent ejaculation — PSA can rise transiently after ejaculation. Many labs recommend abstaining for 48 hours before testing, though not all providers give this instruction.
Recent prostate exam or procedure — digital rectal exam, catheter insertion, or cystoscopy can temporarily elevate PSA.
Vigorous cycling — sustained perineal pressure from long bike rides is a documented, modest contributor.
Medications that suppress PSA — finasteride and dutasteride (used for BPH or hair loss) can cut PSA values roughly in half 3Ref 3Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010).Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review.Finasteride's suppression of PSA levels, requiring correction when interpreting PSA results in men taking the medication. An apparently "normal" PSA in a man taking these medications may actually be elevated relative to the true baseline — disclosing these medications to your clinician is essential.
What will my clinician likely do after a high PSA?
The approach varies based on the number, your age, prior results, and overall health. Common next steps 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment:
Repeat the PSA — a single elevated value may reflect a transient cause. Many clinicians will repeat it a few weeks later under controlled conditions (no ejaculation 48 hours prior, no recent prostate exam, no active infection) before deciding on further steps.
Digital rectal exam (DRE) — a brief physical exam to feel the prostate for nodules or irregularities. A normal-feeling prostate lowers — but does not eliminate — concern.
PSA refinements — free-to-total PSA ratio, PSA density (adjusted for prostate size), and PSA velocity (how much it has risen over time) help distinguish benign from concerning elevations.
Urology referral — if the number is significantly elevated, rising, or combined with concerning exam findings, your primary-care clinician may refer you to a urologist for further evaluation.
Prostate MRI — increasingly used before or instead of biopsy to characterize suspicious areas and reduce unnecessary biopsies.
Prostate biopsy — the only definitive way to detect or exclude prostate cancer; recommended based on risk assessment, not automatically for any single elevated PSA.
Why is shared decision-making central to this conversation?
PSA follow-up involves real trade-offs 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. Biopsies carry small risks of infection and discomfort. Prostate cancer found through screening is sometimes slow-growing and may never cause symptoms in a man's lifetime, while other prostate cancers are aggressive and need treatment.
Major guidelines emphasize that men should make decisions about PSA follow-up in an informed conversation with their clinician — weighing age, life expectancy, family history, and personal values around risk and intervention 1Ref 1Wei JT, Barocas D, Carlsson S, et al. (2023).Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups2Ref 2US Preventive Services Task Force (2018).Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment. If your clinician presents you with a genuine choice about next steps, that is not evasion — it reflects the fact that reasonable men may choose differently based on their priorities.
This is a good moment to ask questions and make sure you understand what each option involves before agreeing to any next step.
Common questions
Does an elevated PSA mean I have prostate cancer?
Not necessarily — and most men with an elevated PSA do not have prostate cancer. It means further evaluation is warranted to understand what is raising the level. Benign prostate enlargement, inflammation, and temporary factors are more common causes of mild to moderate elevation than cancer.
Should I see a urologist, or is my primary care doctor enough?
For a mildly elevated PSA without other concerning features, your primary-care clinician can often manage the initial evaluation — repeating the test, doing a rectal exam, and monitoring the trend. Urology referral is appropriate if the PSA is significantly elevated, rising, combined with an abnormal exam, or if a biopsy or MRI is being considered.
How worried should I be while waiting for follow-up?
For most men with a mildly elevated PSA and no symptoms, the likelihood of a serious finding is relatively low and follow-up can be done at a planned appointment rather than urgently. Focus on gathering your prior PSA results to bring to the conversation — the trend over time is one of the most useful pieces of information.
Can I do anything to prepare for a repeat PSA test?
Yes. For a more accurate result, avoid ejaculation for 48 hours before the test, avoid vigorous cycling in the days prior, do not have a prostate exam immediately before the blood draw, and make sure any active urinary infections are treated beforehand. Tell the clinician ordering the test if you take finasteride or dutasteride.
Talk to a clinician
Nina Osei, NP — Nurse Practitioner
checkups, refills & skin. Gale can match you with a licensed clinician for a visit.
Find care →Symptoms that need prompt evaluation — do not wait for a scheduled appointment
- —Inability to urinate at all (urinary retention) — seek urgent care
- —Blood in the urine or semen — get evaluated promptly
- —New bone pain in the back, hips, or pelvis in a man with a known or suspected prostate condition — mention to your clinician soon
- —Fever, chills, and pain with urination — possible prostate infection requiring same-day care
This article provides general health information only and is not a diagnosis or personalized medical advice. PSA interpretation must be done by a licensed clinician who has your full history and prior results.
References
- 1.Wei JT, Barocas D, Carlsson S, et al. (2023). Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Journal of Urology. doi:10.1097/JU.0000000000003491 ✓Non-specific nature of PSA; preferred interpretive tools (velocity, density, free-to-total ratio); repeat testing strategy; MRI before biopsy; shared decision-making; higher-risk groups
- 2.US Preventive Services Task Force (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. doi:10.1001/jama.2018.3710 ✓Shared decision-making emphasis; trade-offs between benefits and harms of PSA follow-up including biopsy risks and over-treatment
- 3.Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G (2010). Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Archives of Dermatology. doi:10.1001/archdermatol.2010.256 ✓Finasteride's suppression of PSA levels, requiring correction when interpreting PSA results in men taking the medication
3 sources, numbered by first appearance. General health information, not medical advice — synthetic demonstration content.